Satrajit Roychoudhury
Overview
Explore the profile of Satrajit Roychoudhury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
9115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomassen D, Roychoudhury S, Amdal C, Reynders D, Musoro J, Sauerbrei W, et al.
BMC Med Res Methodol
. 2025 Mar;
25(1):56.
PMID: 40025441
Introduction: As patient-reported outcomes (PROs) are increasingly used in the evaluation of medical treatments, it is important that PROs are carefully analyzed and interpreted. This may be challenging due to...
2.
Thomassen D, Roychoudhury S, Amdal C, Reynders D, Musoro J, Sauerbrei W, et al.
BMC Med Res Methodol
. 2024 Nov;
24(1):290.
PMID: 39580440
Background: Patient-reported outcomes (PROs) play an increasing role in the evaluation of oncology treatments. At the same time, single-arm trials are commonly included in regulatory approval submissions. Because of the...
3.
Ye J, Pan H, Reaman G, Roychoudhury S, Lu C, Renfro L, et al.
Med Res Arch
. 2024 Jul;
12(1).
PMID: 39026931
Pediatric cancer consists of a diverse group of rare diseases. Due to limited patient populations, standard randomized and controlled trials are often infeasible. As a result, single-arm trials are common...
4.
Wei W, Zhang Y, Roychoudhury S
Stat Med
. 2024 Jun;
43(20):3815-3829.
PMID: 38924575
Among clinical trialists, there has been a growing interest in using external data to improve decision-making and accelerate drug development in randomized clinical trials (RCTs). Here we propose a novel...
5.
Patel P, Macdonald J, Boobalan J, Marsden M, Rizzi R, Zenon M, et al.
Front Med (Lausanne)
. 2023 Nov;
10:1275817.
PMID: 38020129
The appropriate use of regulatory agilities has the potential to accelerate regulatory review, utilize resources more efficiently and deliver medicines and vaccines more rapidly, all without compromising quality, safety and...
6.
Soltantabar P, Alhadab A, Hibma J, Roychoudhury S, Wang D, Bello C, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Oct;
12(12):2001-2012.
PMID: 37794707
Exposure-response (E-R) analyses are an integral component of understanding the benefit/risk profile of novel oncology therapeutics. These analyses are typically conducted using data from the treatment arm to characterize the...
7.
Weber H, Corson S, Li J, Mercier F, Roychoudhury S, Sailer M, et al.
Pharm Stat
. 2023 Oct;
23(1):91-106.
PMID: 37786317
Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the best overall response...
8.
Quiroz J, Roychoudhury S, Steinmetz T, Yang H
Pharm Stat
. 2023 Jul;
22(6):978-994.
PMID: 37415413
The response of immunogenecity anti-drug antibody (ADA) generally includes biological and analytical variability. The nature of biological and analytical variations may lead to a variety of symmetric and asymmetric ADA...
9.
Wang S, Kidwell K, Roychoudhury S
Biometrics
. 2023 Jun;
79(4):3612-3623.
PMID: 37323055
In Duchenne muscular dystrophy (DMD) and other rare diseases, recruiting patients into clinical trials is challenging. Additionally, assigning patients to long-term, multi-year placebo arms raises ethical and trial retention concerns....
10.
Pe M, Alanya A, Falk R, Amdal C, Bjordal K, Chang J, et al.
Lancet Oncol
. 2023 Jun;
24(6):e270-e283.
PMID: 37269858
Patient-reported outcomes (PROs), such as symptoms, functioning, and other health-related quality-of-life concepts are gaining a more prominent role in the benefit-risk assessment of cancer therapies. However, varying ways of analysing,...